48 results on '"Mlakar V"'
Search Results
2. Genome-wide gene expression profiling of low-dose, long-term exposure of human osteosarcoma cells to bisphenol A and its analogs bisphenols AF and S
- Author
-
Fic, A., Jurković Mlakar, S., Juvan, P., Mlakar, V., Marc, J., Sollner Dolenc, M., Broberg, K., and Peterlin Mašič, L.
- Published
- 2015
- Full Text
- View/download PDF
3. Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation
- Author
-
Mlakar, S.J., Uppugunduri, S.C.R., Nava, T., Mlakar, V., Golay, H., Robin, S., Waespe, N., Rezgui, M.A., Chalandon, Y., Boelens, J.J., Bredius, R.G.M., Dalle, J.H., Peters, C., Corbacioglu, S., Bittencourt, H., Krajinovic, M., Ansari, M., and European Soc Blood Marrow Transpla
- Subjects
Cancer Research ,Oncology ,General Medicine - Published
- 2021
4. Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation
- Author
-
Uppugunduri, C. R. S., primary, Huezo-Diaz Curtis, P., additional, Nava, T., additional, Rezgui, M. A., additional, Mlakar, V., additional, Mlakar, S. Jurkovic, additional, Waespe, N., additional, Théoret, Y., additional, Gumy-Pause, F., additional, Bernard, F., additional, Chalandon, Y., additional, Boelens, J. J., additional, Bredius, R. G. M., additional, Dalle, J. H., additional, Nath, C., additional, Corbacioglu, S., additional, Peters, C., additional, Bader, P., additional, Shaw, P., additional, Bittencourt, H., additional, Krajinovic, M., additional, and Ansari, M., additional
- Published
- 2021
- Full Text
- View/download PDF
5. CALM3 promoter methylation associates with genes down-regulation in patients with colorectal cancer: P13-23
- Author
-
Hrašovec, S., Mlakar, V., and Glavac, D.
- Published
- 2012
6. 4th ESPT summer school: precision medicine and personalised health
- Author
-
Mlakar, V., Marc, J. (Janja), Manolopoulos, V.G. (Vangelis), Cascorbi, I., Stankovic, S., Llerena, A. (Adrián), Simmaco, M, Visvikis-Siest, S. (Sophie), Amstutz, U., Sipeky, C., Meyer, U. A., Meier-Abt, P., Schaik, R.H.N. (Ron) van, Ansari, M. (Morad), Mlakar, V., Marc, J. (Janja), Manolopoulos, V.G. (Vangelis), Cascorbi, I., Stankovic, S., Llerena, A. (Adrián), Simmaco, M, Visvikis-Siest, S. (Sophie), Amstutz, U., Sipeky, C., Meyer, U. A., Meier-Abt, P., Schaik, R.H.N. (Ron) van, and Ansari, M. (Morad)
- Published
- 2019
- Full Text
- View/download PDF
7. 4th ESPT summer school: precision medicine and personalised health
- Author
-
Mlakar, V, Marc, J, Manolopoulos, VG, Cascorbi, I, Stankovic, S, LLerena, A, Simmaco, M, Visvikis-Siest, S, Amstutz, U, Sipeky, C, Meyer, U A, Meier-Abt, P, van Schaik, Ron, Ansari, M, Mlakar, V, Marc, J, Manolopoulos, VG, Cascorbi, I, Stankovic, S, LLerena, A, Simmaco, M, Visvikis-Siest, S, Amstutz, U, Sipeky, C, Meyer, U A, Meier-Abt, P, van Schaik, Ron, and Ansari, M
- Published
- 2019
8. 8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016
- Author
-
Visvikis-Siest, S. (Sophie), Aldasoro Arguinano, A.-A. (Alex-Ander), Stathopoulou, M.G. (Maria G), Xie, T. (Ting), Petrelis, A. (Alexandros), Weryha, G. (Georges), Froguel, P. (Philippe), Meier-Abt, P. (Peter), Meyer, U. (Urs), Mlakar, V. (Vid), Ansari, M. (Marc), Papassotiropoulos, A. (Andreas), Dedoussis, G.V. (George), Pan, B. (Baishen), Bühlmann, R.P. (Roland P.), Noyer-Weidner, M. (Mario), Dietrich, P.-Y. (Pierre-Yves), Schaik, R.H.N. (Ron) van, Innocenti, F. (Francesco), März, W. (Winfried), Bekris, L. (Lynn), Deloukas, P. (Panagiotis), Visvikis-Siest, S. (Sophie), Aldasoro Arguinano, A.-A. (Alex-Ander), Stathopoulou, M.G. (Maria G), Xie, T. (Ting), Petrelis, A. (Alexandros), Weryha, G. (Georges), Froguel, P. (Philippe), Meier-Abt, P. (Peter), Meyer, U. (Urs), Mlakar, V. (Vid), Ansari, M. (Marc), Papassotiropoulos, A. (Andreas), Dedoussis, G.V. (George), Pan, B. (Baishen), Bühlmann, R.P. (Roland P.), Noyer-Weidner, M. (Mario), Dietrich, P.-Y. (Pierre-Yves), Schaik, R.H.N. (Ron) van, Innocenti, F. (Francesco), März, W. (Winfried), Bekris, L. (Lynn), and Deloukas, P. (Panagiotis)
- Published
- 2017
- Full Text
- View/download PDF
9. Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT)
- Author
-
Amstutz, U. (Ursula), Mlakar, V. (Vid), Curtis, P.H.-D. (Patricia Huezo-Diaz), Samer, C.F. (Caroline F.), Baumann, P. (Pierre), Bühlmann, R.P. (Roland P.), Meier-Abt, P. (Peter), Meyer, U.A. (Urs A.), Schaik, R.H.N. (Ron) van, Ansari, M. (Marc), Amstutz, U. (Ursula), Mlakar, V. (Vid), Curtis, P.H.-D. (Patricia Huezo-Diaz), Samer, C.F. (Caroline F.), Baumann, P. (Pierre), Bühlmann, R.P. (Roland P.), Meier-Abt, P. (Peter), Meyer, U.A. (Urs A.), Schaik, R.H.N. (Ron) van, and Ansari, M. (Marc)
- Published
- 2017
- Full Text
- View/download PDF
10. Crack development and acoustic emission in potash rock
- Author
-
Mlakar, V., primary, Hassani, F.P., additional, and Momayez, M., additional
- Published
- 1993
- Full Text
- View/download PDF
11. Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells
- Author
-
Glavac Damjan, Cemazar Maja, Todorovic Vesna, Mlakar Vid, and Sersa Gregor
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Electroporation is a versatile method for in vitro or in vivo delivery of different molecules into cells. However, no study so far has analysed the effects of electric pulses used in electrochemotherapy (ECT pulses) or electric pulses used in electrogene therapy (EGT pulses) on malignant cells. We studied the effect of ECT and EGT pulses on human malignant melanoma cells in vitro in order to understand and predict the possible effect of electric pulses on gene expression and their possible effect on cell behaviour. Methods We used microarrays with 2698 different oligonucleotides to obtain the expression profile of genes involved in apoptosis and cancer development in a malignant melanoma cell line (SK-MEL28) exposed to ECT pulses and EGT pulses. Results Cells exposed to ECT pulses showed a 68.8% average survival rate, while cells exposed to EGT pulses showed a 31.4% average survival rate. Only seven common genes were found differentially expressed in cells 16 h after exposure to ECT and EGT pulses. We found that ECT and EGT pulses induce an HSP70 stress response mechanism, repress histone protein H4, a major protein involved in chromatin assembly, and down-regulate components involved in protein synthesis. Conclusion Our results show that electroporation does not significantly change the expression profile of major tumour suppressor genes or oncogenes of the cell cycle. Moreover, electroporation also does not changes the expression of genes involved in the stability of DNA, supporting current evidence that electroporation is a safe method that does not promote tumorigenesis. However, in spite of being considered an isothermal method, it does to some extent induce stress, which resulted in the expression of the environmental stress response mechanism, HSP70.
- Published
- 2009
- Full Text
- View/download PDF
12. Presence of activating KRAS mutations correlates significantly with expression of tumour suppressor genes DCN and TPM1 in colorectal cancer
- Author
-
Rems Miran, Štor Zdravko, Volavšek Metka, Berginc Gašper, Mlakar Vid, and Glavač Damjan
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Despite identification of the major genes and pathways involved in the development of colorectal cancer (CRC), it has become obvious that several steps in these pathways might be bypassed by other as yet unknown genetic events that lead towards CRC. Therefore we wanted to improve our understanding of the genetic mechanisms of CRC development. Methods We used microarrays to identify novel genes involved in the development of CRC. Real time PCR was used for mRNA expression as well as to search for chromosomal abnormalities within candidate genes. The correlation between the expression obtained by real time PCR and the presence of the KRAS mutation was investigated. Results We detected significant previously undescribed underexpression in CRC for genes SLC26A3, TPM1 and DCN, with a suggested tumour suppressor role. We also describe the correlation between TPM1 and DCN expression and the presence of KRAS mutations in CRC. When searching for chromosomal abnormalities, we found deletion of the TPM1 gene in one case of CRC, but no deletions of DCN and SLC26A3 were found. Conclusion Our study provides further evidence of decreased mRNA expression of three important tumour suppressor genes in cases of CRC, thus implicating them in the development of this type of cancer. Moreover, we found underexpression of the TPM1 gene in a case of CRCs without KRAS mutations, showing that TPM1 might serve as an alternative path of development of CRC. This downregulation could in some cases be mediated by deletion of the TPM1 gene. On the other hand, the correlation of DCN underexpression with the presence of KRAS mutations suggests that DCN expression is affected by the presence of activating KRAS mutations, lowering the amount of the important tumour suppressor protein decorin.
- Published
- 2009
- Full Text
- View/download PDF
13. Electric pulses used in electrochemotherapy and electrogene therapy do not significantly change the expression profile of genes involved in the development of cancer in malignant melanoma cells.
- Author
-
Mlakar V, Todorovic V, Cemazar M, Glavac D, Sersa G, Mlakar, Vid, Todorovic, Vesna, Cemazar, Maja, Glavac, Damjan, and Sersa, Gregor
- Abstract
Background: Electroporation is a versatile method for in vitro or in vivo delivery of different molecules into cells. However, no study so far has analysed the effects of electric pulses used in electrochemotherapy (ECT pulses) or electric pulses used in electrogene therapy (EGT pulses) on malignant cells. We studied the effect of ECT and EGT pulses on human malignant melanoma cells in vitro in order to understand and predict the possible effect of electric pulses on gene expression and their possible effect on cell behaviour.Methods: We used microarrays with 2698 different oligonucleotides to obtain the expression profile of genes involved in apoptosis and cancer development in a malignant melanoma cell line (SK-MEL28) exposed to ECT pulses and EGT pulses.Results: Cells exposed to ECT pulses showed a 68.8% average survival rate, while cells exposed to EGT pulses showed a 31.4% average survival rate. Only seven common genes were found differentially expressed in cells 16 h after exposure to ECT and EGT pulses. We found that ECT and EGT pulses induce an HSP70 stress response mechanism, repress histone protein H4, a major protein involved in chromatin assembly, and down-regulate components involved in protein synthesis.Conclusion: Our results show that electroporation does not significantly change the expression profile of major tumour suppressor genes or oncogenes of the cell cycle. Moreover, electroporation also does not changes the expression of genes involved in the stability of DNA, supporting current evidence that electroporation is a safe method that does not promote tumorigenesis. However, in spite of being considered an isothermal method, it does to some extent induce stress, which resulted in the expression of the environmental stress response mechanism, HSP70. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
14. Neuroblastoma response to RAS-MAPK inhibitors and APR-246 (eprenetapopt) co-treatment is dependent on SLC7A11.
- Author
-
Mlakar V, Oehme I, Lesne L, Najafi S, Ansari M, and Gumy-Pause F
- Abstract
Background: We previously demonstrated that APR-246 (eprenetapopt) could be an efficient treatment option against neuroblastoma (NB), the most common pediatric extracranial solid tumor. APR-246's mechanism of action is not completely understood and can differ between cell types. Here we investigate the involvement of well-known oncogenic pathways in NB's response to APR-246., Methods: A proteome profiler kinase assays and western blot analysis were used to identify the molecular pathways involved in the responses to APR-246. Bulk ATP levels were used to determine the viability of cells and the IC
50 for APR-246. Cystine-FITC was used to measure the cellular uptake of cysteine. PmRNA5 was used to activate ERK1/2 and pshRNA1 was used to silence HSP27. An IMR-32 xenograft zebrafish embryo model was used to assess APR-246 and sulfasalazine efficacy in vivo ., Results: After APR-246 treatment, the most deregulated signaling protein identified was ERK1/2, an end-point kinase of the RAS-MAPK pathway. Induction of phospho-ERK1/2 resulted in increased glutathione (GSH) levels, increased cystine uptake, and increased resistance of NB cells to APR-246. Using ERK1/2 inhibitors in combination with APR-246, we were able to categorize cells into synergistic and antagonistic groups. After co-treatment, these two groups differ by their levels of SLC7A11 and Hsp27 phosphorylation, cystine uptake, and BIM expression. Using erastin and sulfasalazine, both inhibitors of SLC7A11 and activators of ferroptosis, we were able to reverse the antagonistic effects of ERK1/2 inhibitors and demonstrate a strong synergistic action in vitro and in vivo in zebrafish models., Conclusions: These results demonstrated a pivotal role of the RAS-MAPK pathway in the NB cellular response to APR-246 via the modulation of intracellular concentrations of GSH and the transport of cystine through SLC7A11, phosphorylation of Hsp27, and programmed cell death. Combining APR-246 with RAS-MAPK pathway inhibitors can, in some cases, lead to antagonistic action, which can be reversed by combining APR-246 with the clinically approved drug sulfasalazine., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Mlakar, Oehme, Lesne, Najafi, Ansari and Gumy-Pause.)- Published
- 2024
- Full Text
- View/download PDF
15. Microcavity-assisted cloning (MAC) of hard-to-clone HepG2 cell lines: cloning made easy.
- Author
-
Mlakar V, Lesne L, Vossio S, Dupanloup I, Gloor Y, Moreau D, and Ansari M
- Subjects
- Humans, Hep G2 Cells, Cloning, Molecular methods, Gene Knockout Techniques methods, Glutathione Transferase genetics, Glutathione Transferase metabolism, Cell Culture Techniques methods, Clone Cells, CRISPR-Cas Systems genetics
- Abstract
Cloning is a key molecular biology procedure for obtaining a genetically homogenous population of organisms or cell lines. It requires the expansion of new cell populations starting from single genetically modified cells. Despite the technical progress, cloning of many cell lines remains difficult. Cloning often fails either due to the strenuous conditions associated with manipulating cells or because many cells don't tolerate a single-cell state. Here we describe a new cloning method utilizing low adhesion microcavity plates. This new technique, named microcavity-assisted cloning (MAC) was developed to clone difficult-to-clone HepG2 cells. The clones were produced following CRISPR/Cas9 knockout of the GSTA1 gene by a random distribution of 200, 400, and 800 cells into 550 microcavities of a 24-well low adhesion plate originally designed for the culture of spheroids. The knockout of GSTA1 was verified at the protein level using Western blotting. The advantages of the MAC method are its low cost, ease of the procedure, and the possibility of scaling up the throughput and automatization., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
16. Telomere biology and its maintenance in schizophrenia spectrum disorders: Exploring links to cognition.
- Author
-
Mlakar V, Akkouh I, Halff EF, Srivastava DP, Birkenæs V, Ueland T, Quintana DS, Ormerod MBEG, Steen NE, Djurovic S, Andreassen OA, and Aas M
- Subjects
- Humans, Female, Male, Adult, Middle Aged, RNA genetics, Cognitive Dysfunction etiology, Cognitive Dysfunction genetics, Cognitive Dysfunction physiopathology, Leukocytes metabolism, Neuropsychological Tests, Telomere Homeostasis physiology, Schizophrenic Psychology, Telomere Shortening physiology, Psychotic Disorders genetics, Psychotic Disorders physiopathology, Telomerase genetics, Schizophrenia genetics, Schizophrenia physiopathology, Telomere
- Abstract
Objective: Contemporary research suggests reduced telomere length in schizophrenia spectrum disorders (SZ) compared to age-adjusted non-affected individuals. However, the role of telomere maintenance and telomere repair in SZ is poorly understood as well as the involvement of telomere biology in cognitive abnormalities in SZ., Methods: The study consisted of 758 participants (SZ [n = 357] and healthy controls, HC [n = 401]) collected as part of the Norwegian TOP study. Participants were assessed with standardized neuropsychological tests measuring five cognitive domains. Leucocyte telomere length (TL) was measured via blood and determined by quantitative real-time Polymerase Chain Reaction (qPCR) providing a telomere to single copy ratio (T/S ratio), used to estimate the mean telomere length. Telomerase activity was assessed by the expression levels of the Telomerase Reverse Transcriptase (TERT) and Telomerase RNA Component (TERC) genes. To assess telomere maintenance and telomere repair we calculated the telomerase expression to TL ratio (TERT/TL and TERC/TL respectively)., Results: Patients had reduced TERT (F = 5.03, p = 0.03), but not TERC expression (F = 1.04, p = 0.31), and higher TERT/TL (F = 6.68, p = 0.01) and TERC/TL (F = 6.71, p = 0.01), adjusted for age, sex, and ethnicity. No statistically significant association was observed between any of the telomere biology markers and the cognitive domains (p > 0.05)., Conclusion: Our study shows changes in TERT expression and telomere maintenance and telomere repair in SZ compared HC. However, the role of telomere biology in the mechanism underlying cognitive impairment in psychosis seems limited., Competing Interests: Declaration of competing interest Authors declare no conflict of interests., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. Haplotype Inference Using Long-Read Nanopore Sequencing: Application to GSTA1 Promoter.
- Author
-
Mlakar V, Dupanloup I, Gloor Y, and Ansari M
- Abstract
Recovering true haplotypes can have important clinical consequences. The laboratory process is difficult and is, therefore, most often done through inference. In this paper, we show that when using the Oxford nanopore sequencing technology, we could recover the true haplotypes of the GSTA1 promoter region. Eight LCL cell lines with potentially ambiguous haplotypes were used to characterize the efficacy of Oxford nanopore sequencing to phase the correct GSTA1 promoter haplotypes. The results were compared to Sanger sequencing and inferred haplotypes in the 1000 genomes project. The average read length was 813 bp out of a total PCR length of 1336 bp. The best coverage of sequencing was in the middle of the PCR product and decreased to 50% at the PCR ends. SNPs separated by less than 200 bp showed > 90% of correct haplotypes, while at the distance of 1089 bp, this proportion still exceeded 58%. The number of cycles influences the generation of hybrid haplotypes but not extension or annealing time. The results demonstrate that this long sequencing reads methodology, can accurately determine the haplotypes without the need for inference. The technology proved to be robust but the success of phasing nonetheless depends on the distances and frequencies of SNPs., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
18. 17q Gain in Neuroblastoma: A Review of Clinical and Biological Implications.
- Author
-
Mlakar V, Dupanloup I, Gonzales F, Papangelopoulou D, Ansari M, and Gumy-Pause F
- Abstract
Neuroblastoma (NB) is the most frequent extracranial solid childhood tumor. Despite advances in the understanding and treatment of this disease, the prognosis in cases of high-risk NB is still poor. 17q gain has been shown to be the most frequent genomic alteration in NB. However, the significance of this remains unclear because of its high frequency and association with other genetic modifications, particularly segmental chromosomal aberrations, 1p and 11q deletions, and MYCN amplification, all of which are also associated with a poor clinical prognosis. This work reviewed the evidence on the clinical and biological significance of 17q gain. It strongly supports the significance of 17q gain in the development of NB and its importance as a clinically relevant marker. However, it is crucial to distinguish between whole and partial chromosome 17q gains. The most important breakpoints appear to be at 17q12 and 17q21. The former distinguishes between whole and partial chromosome 17q gain; the latter is a site of IGF2BP1 and NME1 genes that appear to be the main oncogenes responsible for the functional effects of 17q gain., Competing Interests: All authors declare no conflicts of interest.
- Published
- 2024
- Full Text
- View/download PDF
19. Telomere length and verbal learning in bipolar disorders.
- Author
-
Mlakar V, Birkenæs V, Elvsaashagen T, Ormerod MBEG, Quintana DS, Ueland T, Melle I, Lagerberg TV, Djurovic S, Martin-Ruiz C, Steen NE, Andreassen OA, and Aas M
- Subjects
- Humans, Telomere Shortening, Telomere, Neuropsychological Tests, Memory, Short-Term, Verbal Learning, Bipolar Disorder drug therapy
- Abstract
Introduction: Recent studies indicate accelerated ageing processes, shorter telomere length and poorer cognitive functioning in patients with bipolar disorder. The neurobiology underlying cognitive function in bipolar disorder is yet to be established. We anticipated that accelerated ageing as indicated by shortened telomere length, would be associated with reduced cognitive performance in bipolar disorder, particularly for ageing sensitive functions such as memory and learning., Methods: The study consisted of 647 participants (bipolar disorder [n = 246] and healthy controls [n = 401]). All participants underwent a standardized neuropsychological test battery, including working memory, executive functioning, processing speed, verbal learning, and verbal memory. Leucocyte telomere length was measured via blood and determined by quantitative real-time Polymerase Chain Reaction (qPCR) providing a telomere to single copy ratio (T/S ratio). The T/S ratio was used as an estimate of the mean telomere length of each participant. All analyses were adjusted for medication, Daily Defined Dose (DDD), chronological age, sex, and ethnicity., Results: Patients had shorter telomere lengths than healthy controls (Cohen's d = 0.11, p = 0.01). Within patients', a positive association was observed for verbal learning and telomere length (β = 0.14, p = 0.025), along with a trend for verbal memory and telomere length (β = 0.11, p = 0.07). No other associations were observed for telomere length and cognitive functioning in the patient or the control group (p > 0.1)., Conclusion: Our study may suggest poorer brain health in bipolar disorder as indexed by shorter telomere length and reduced learning correlates. However, the role of telomere length on cognitive functioning in bipolar disorder seems limited., Competing Interests: Declaration of competing interest No conflicts of interest., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Correction to: GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
- Author
-
Jurkovic Mlakar S, Uppugunduri SCR, Nava T, Mlakar V, Golay H, Robin S, Waespe N, Rezgui MA, Chalandon Y, Boelens JJ, Bredius RGM, Dalle JH, Peters C, Corbacioglu S, Bittencourt H, Krajinovic M, and Ansari M
- Published
- 2022
- Full Text
- View/download PDF
21. GSTM1 and GSTT1 double null genotypes determining cell fate and proliferation as potential risk factors of relapse in children with hematological malignancies after hematopoietic stem cell transplantation.
- Author
-
Jurkovic Mlakar S, Uppugunduri SCR, Nava T, Mlakar V, Golay H, Robin S, Waespe N, Rezgui MA, Chalandon Y, Boelens JJ, Bredius RGM, Dalle JH, Peters C, Corbacioglu S, Bittencourt H, Krajinovic M, and Ansari M
- Subjects
- Adolescent, Biomarkers, Tumor genetics, Busulfan therapeutic use, Cell Line, Tumor, Cell Proliferation genetics, Child, Child, Preschool, Drug Resistance, Neoplasm genetics, Female, Gene Deletion, Genetic Predisposition to Disease genetics, Genotype, Glutathione analysis, Glutathione metabolism, Hematologic Neoplasms pathology, Hematologic Neoplasms therapy, Hematopoietic Stem Cell Transplantation, Humans, Infant, Leukemia pathology, Leukemia therapy, Male, Retrospective Studies, Risk Factors, Glutathione Transferase genetics, Hematologic Neoplasms genetics, Leukemia genetics, Neoplasm Recurrence, Local genetics
- Abstract
Purpose: This study aimed to retrospectively evaluate the genetic association of null variants of glutathione S-transferases GSTM1 and GSTT1 with relapse incidence in children with hematological malignancies (HMs) undergoing busulfan (BU)- containing allogeneic hematopoietic stem cell transplantation (HSCT) and to assess the impact of these variants on BU-induced cytotoxicity on the immortalized lymphoblastoid cell lines (LCLs) and tumor THP1 GST gene-edited cell models., Methods: GSTM1- and GSTT1-null alleles were genotyped using germline DNA from whole blood prior to a conditioning BU-based regimen. Association of GSTM1- and GSTT1-null variants with relapse incidence was analyzed using multivariable competing risk analysis. BU-induced cell death studies were conducted in GSTs- null and non-null LCLs and CRISPR-Cas9 gene-edited THP1 leukemia cell lines., Results: Carrying GSTM1/GSTT1 double null genotype was found to be an independent risk factor for post-HSCT relapse in 86 children (adjusted HR: 6.52 [95% Cl, 2.76-15.42; p = 1.9 × 10
-5 ]). BU-induced cell death preferentially in THP1GSTM1(non-null) and LCLsGSTM1(non-null) as shown by decreased viability, increased necrosis and levels of the oxidized form of glutathione compared to null cells, while GSTT1 non-null cells showed increased baseline proliferation., Conclusion: The clinical association suggests that GSTM1/GSTT1 double null genotype could serve as genetic stratification biomarker for the high risk of post-HSCT relapse. Functional studies have indicated that GSTM1 status modulates BU-induced cell death. On the other hand, GSTT1 is proposed to be involved in baseline cell proliferation., (© 2021. The Author(s).)- Published
- 2022
- Full Text
- View/download PDF
22. A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma.
- Author
-
Mlakar V, Morel E, Mlakar SJ, Ansari M, and Gumy-Pause F
- Subjects
- Humans, MAP Kinase Signaling System genetics, Neuroblastoma genetics
- Abstract
Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcriptomics studies have demonstrated the RAS-MAPK pathway's contribution to the development and progression of neuroblastoma. This review compiles up-to-date evidence of this pathway's involvement in neuroblastoma. We discuss the RAS-MAPK pathway's general functioning, the clinical implications of its deregulation in neuroblastoma, and current promising therapeutics targeting proteins involved in signaling.
- Published
- 2021
- Full Text
- View/download PDF
23. The analysis of GSTA1 promoter genetic and functional diversity of human populations.
- Author
-
Mlakar V, Curtis PH, Armengol M, Ythier V, Dupanloup I, Hassine KB, Lesne L, Murr R, Mlakar SJ, Nava T, and Ansari M
- Subjects
- Africa, Americas, Asia, Binding Sites, Europe, Gene Expression Regulation, Genes, Reporter, Glutathione Transferase metabolism, Haplotypes, Hep G2 Cells, Humans, Luciferases genetics, Luciferases metabolism, Protein Binding, Transcription Factors genetics, Transcription Factors metabolism, Transcription, Genetic, Genetics, Population, Genome, Human, Glutathione Transferase genetics, Polymorphism, Single Nucleotide, Promoter Regions, Genetic
- Abstract
GSTA1 encodes a member of a family of enzymes that function to add glutathione to target electrophilic compounds, including carcinogens, therapeutic drugs, environmental toxins, and products of oxidative stress. GSTA1 has several functional SNPs within its promoter region that are responsible for a change in its expression by altering promoter function. This study aims to investigate distributions of GSTA1 promoter haplotypes across different human populations and to assess their impact on the expression of GSTA1. PHASE 2.1.1 was used to infer haplotypes and diplotypes of six GSTA1 promoter SNPs on 2501 individuals from 26 populations classified by the 1000 Genomes Project into five super-populations that included Africa (N = 660), America (N = 347), East Asia (N = 504), Europe (N = 502), and South Asia (N = 488). We used pairwise FST analysis to compare sub-populations and luciferase reporter assay (LRA) to evaluate the impact of each SNP on activation of transcription and interaction with other SNPs. The distributions of GSTA1 promoter haplotypes and diplotypes were significantly different among the different human populations. Three new promoter haplotypes were found in the African super-population. LRA demonstrated that SNPs at -52 and -69 has the most impact on GSTA1 expression, however other SNPs have a significant impact on transcriptional activity. Based on LRA, a new model of cis-elements interaction is presented. Due to the significant differences in GSTA1 diplotype population frequencies, future pharmacogenomics or disease-related studies would benefit from the inclusion of the complete GSTA1 promoter haplotype based on the newly proposed metabolic grouping derived from the LRA results.
- Published
- 2021
- Full Text
- View/download PDF
24. The Catalytic Activity of GSTM1 In vitro is Independent of MAPK8.
- Author
-
Robin S, Ben Hassine K, Mlakar SJ, Mlakar V, Ansari M, and Uppugunduri CRS
- Subjects
- Amino Acids, Humans, Protein Isoforms, Glutathione Transferase, Mitogen-Activated Protein Kinase 8
- Abstract
Background: Glutathione S-transferases (GSTs) are phase II metabolic enzymes crucial for the metabolism of electrophilic drugs. Additionally, several GST isoforms are involved in protein- protein interaction with mitogen-activated protein kinases (MAPKs), modulating apoptosis pathways., Methods: To assess the potential change of enzymatic activity, we performed a GST enzyme assay with human recombinant GSTM1 in the presence and absence of MAPK8. Recently, GSTM1 has been demonstrated to interact with MAPK8 both in silico and in vitro. The binding interface predicted in silico comprised amino acid residues present on the surface of the protein and a few were deep in the active site of the protein., Results: The experiment demonstrated that the GSTM1 activity was conserved even in the presence of MAPK8 in the assay., Conclusion: The possible alteration in the activity of MAPK8 in this interaction needs to be evaluated in further experiments., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2021
- Full Text
- View/download PDF
25. 4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.
- Author
-
Sipeky C, Llerena A, Manolopoulos VG, Pearson E, Mlakar V, Gozzo L, Simmaco M, Marchetti P, Re MD, Stankovic S, Meyer U, Cascorbi I, Ingelman-Sundberg M, Suarez-Kurtz G, Marc J, Katsila T, Paulmichl M, Nofziger C, Ansari M, Drago F, and van Schaik RH
- Subjects
- Humans, Pharmacogenetics methods, Precision Medicine methods
- Abstract
The Fourth European Society of Pharmacogenomics and Personalized Therapy biennial conference was organized in collaboration with the Italian Society of Personalized Medicine (SIMeP) and was held at Benedictine Monastery of San Nicolò l'Arena in Catania, Sicily (Italy) on 4-7 October 2017. The congress addressed the research progress and clinical implementation in pharmacogenomics and personalized medicine. The Fourth European Society of Pharmacogenomics and Personalized Therapy congress brought together leading international scientists and healthcare professionals actively working in the fields of pharmacogenomics and personalized therapy. Altogether, 25 speakers in 15 session comprehensively covered broad spectrum of pharmacogenetics and pharmacogenomics research, clinical applications in different clinical disciplines attended by 270 delegates.
- Published
- 2019
- Full Text
- View/download PDF
26. Sex-determining region Y (SRY) attributes to gender differences in RANKL expression and incidence of osteoporosis.
- Author
-
Kodrič K, Zupan J, Kranjc T, Komadina R, Mlakar V, Marc J, and Lovšin N
- Subjects
- Bone and Bones metabolism, Bone and Bones pathology, Case-Control Studies, Cells, Cultured, Female, Gene Expression Regulation, HeLa Cells, Humans, Incidence, Male, Osteoporosis genetics, Osteoporosis pathology, Primary Cell Culture, RANK Ligand metabolism, Sex Characteristics, Osteoporosis epidemiology, RANK Ligand genetics, Sex-Determining Region Y Protein physiology
- Abstract
Receptor activator of nuclear factor κB ligand (RANKL) plays a crucial role in bone metabolism. RANKL gene misregulation has been implicated in several bone and cancer diseases. Here, we aimed to identify novel transcription regulators of RANKL expression. We discovered that transcription factors, sex-determining region Y (SRY) and c-Myb, regulate RANKL expression. We demonstrated that c-Myb increases and male-specific SRY decreases RANKL expression through direct binding to its 5'-proximal promoter. These results are corroborated by the gene expression in human bone samples. In osteoporotic men, expression of RANKL is 17-fold higher, which correlates with the drastically reduced expression (200-fold) of Sry, suggesting that in osteoporotic men, the upregulation of RANKL is caused by a decrease of Sry. In healthy men, the expression of RANKL is 20% higher than that in healthy women. Our data suggest that gender differences in RANKL expression and bone quality could be due to the sex-specific transcription factor SRY.
- Published
- 2019
- Full Text
- View/download PDF
27. The Biological and Clinical Relevance of G Protein-Coupled Receptors to the Outcomes of Hematopoietic Stem Cell Transplantation: A Systematized Review.
- Author
-
Golay H, Jurkovic Mlakar S, Mlakar V, Nava T, and Ansari M
- Subjects
- Animals, Hematopoietic Stem Cells cytology, Humans, Treatment Outcome, Hematopoietic Stem Cell Mobilization methods, Hematopoietic Stem Cell Transplantation methods, Receptors, G-Protein-Coupled analysis
- Abstract
Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment for several malignant and non-malignant diseases at the cost of serious treatment-related toxicities (TRTs). Recent research on extending the benefits of HSCT to more patients and indications has focused on limiting TRTs and improving immunological effects following proper mobilization and engraftment. Increasing numbers of studies report associations between HSCT outcomes and the expression or the manipulation of G protein-coupled receptors (GPCRs). This large family of cell surface receptors is involved in various human diseases. With ever-better knowledge of their crystal structures and signaling dynamics, GPCRs are already the targets for one third of the current therapeutic arsenal. The present paper assesses the current status of animal and human research on GPCRs in the context of selected HSCT outcomes via a systematized survey and analysis of the literature.
- Published
- 2019
- Full Text
- View/download PDF
28. Telomerase stability and evaluation of real-time telomeric repeat amplification protocol.
- Author
-
Vukašinović AR, Kotur-Stevuljević JM, Mlakar V, Sopić MD, Cvetković ZP, Petković MR, Spasojević-Kalimanovska VV, Bogavac-Stanojević NB, and Ostanek B
- Subjects
- Cell Line, Enzyme Stability, Humans, Proton Magnetic Resonance Spectroscopy, Reference Standards, Polymerase Chain Reaction methods, Repetitive Sequences, Nucleic Acid genetics, Telomerase metabolism
- Abstract
Telomerase is RNA directed polymerase which acts as reverse transcriptase based on its own RNA component. It is considered to be involved in the pathology of many diseases and is recognized as a potential biomarker. The aims were to determine the sample storage conditions and the time frame for samples analysis, then to prove reliability of enzyme activity measurement with real-time telomeric repeat amplification protocol (TRAP) and to evaluate the suitable standard samples for telomerase activity measurements. Samples used for stability and freeze-thaw study were peripheral blood leukocytes, obtained from apparently healthy persons, patients with diagnosed cancer and cell lines. Telomerase activity was measured using TRAP method, while standard evaluation was done using nuclear magnetic resonance (NMR) technique. Storage at -20 °C preserved telomerase activity in samples from cancer patients for at least 14 days (21.46 ± 0.135 versus 21.84 ± 0.357, p = .756), while samples obtained from healthy persons should be stored at -80 °C. We observed significant decrease of telomerase activity at freeze thaw cycle 5 in cancer patients' samples (21.46 ± 0.135 versus 23.09 ± 0.316, p < .05), and in healthy persons' ones already at cycle 3 (22.74 ± 0.107 versus 24.85 ± 0.151, p < .05). Telomerase activity from cell lines samples showed overall greater stability regarding the storage period and freeze-thaw cycles and it was considered for standard sample, which was confirmed by NMR analysis. Telomerase enzyme had adequate stability while efficacy, linearity, and reproducibility of TRAP method were acceptable for bio-analytical methods. All this indicated that telomerase could be a reliable biomarker.
- Published
- 2019
- Full Text
- View/download PDF
29. 4th ESPT summer school: precision medicine and personalised health.
- Author
-
Mlakar V, Marc J, Manolopoulos VG, Cascorbi I, Stanković S, Llerena A, Simmaco M, Visvikis-Siest S, Amstutz U, Sipeky C, Meyer UA, Meier-Abt P, van Schaik RH, and Ansari M
- Subjects
- Humans, Pharmacogenetics education, Switzerland, Pharmacogenetics trends, Precision Medicine trends
- Abstract
In September 2018, the European Society of Pharmacogenomics and Personalised Therapy (ESPT), with the support of the Swiss Personalized Health Network (SPHN), organized its 4th biennial summer school, entitled 'Precision Medicine and Personalised Health' (Campus Biotech, Geneva, Switzerland; www.esptsummerschool.eu/ ). The school's comprehensive and innovative educational program aimed to address the fundamentals of pharmacogenomics, the latest knowledge on established and new concepts in the field of precision medicine, as well as its advanced clinical applications in personalized health. The school consisted of 31 lectures, eight interactive workshops, visits to genome center and poster presentations, involving 40 speakers from distinguished international faculties. The meeting was a resounding success by generating informal environments between more than 80 participants from 26 different countries.
- Published
- 2019
- Full Text
- View/download PDF
30. PRIMA-1 MET -induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level.
- Author
-
Mlakar V, Jurkovic Mlakar S, Lesne L, Marino D, Rathi KS, Maris JM, Ansari M, and Gumy-Pause F
- Subjects
- Cell Death drug effects, Cell Line, Tumor, Humans, N-Myc Proto-Oncogene Protein genetics, Neuroblastoma genetics, Neuroblastoma metabolism, Neuroblastoma pathology, Thioredoxins genetics, Thioredoxins metabolism, Tumor Suppressor Protein p53 genetics, Glutathione metabolism, N-Myc Proto-Oncogene Protein metabolism, Neuroblastoma drug therapy, Quinuclidines pharmacology, Tumor Suppressor Protein p53 metabolism
- Abstract
Background: Neuroblastoma is the most common extracranial solid tumor in children. This cancer has a low frequency of TP53 mutations and its downstream pathway is usually intact. This study assessed the efficacy of the p53 activator, PRIMA-1
MET , in inducing neuroblastoma cell death., Methods: CellTiter 2.0 was used to study susceptibility and specificity of NB cell lines to PRIMA-1MET . Real-time PCR and western blot were used to assess the most common p53 transactivation targets. Induction of p53 and Noxa, and inhibition of Cas3/7, were used to assess impact on cell death after PRIMA-1MET treatment. Flow cytometry was used to analyze cell cycle phase and induction of apoptosis, reactive oxygen species, and the collapse of mitochondrial membrane potential., Results: Neuroblastoma cell lines were at least four times more susceptible to PRIMA-1MET than were primary fibroblasts and keratinocyte cell lines. PRIMA-1MET induced cell death rapidly and in all cell cycle phases. Although PRIMA-1MET activated p53 transactivation activity, p53's role is likely limited because its main targets remained unaffected, whereas pan-caspase inhibitor demonstrated no ability to prevent cell death. PRIMA-1MET induced oxidative stress and modulated the methionine/cysteine/glutathione axis. Variations of MYCN and p53 modulated intracellular levels of GSH and resulted in increased/decreased sensitivity of PRIMA-1MET . PRIMA-1MET inhibited thioredoxin reductase, but the effect of PRIMA-1MET was not altered by thioredoxin inhibition., Conclusions: PRIMA-1MET could be a promising new agent to treat neuroblastoma because it demonstrated good anti-tumor action. Although p53 is involved in PRIMA-1MET -mediated cell death, our results suggest that direct interaction with p53 has a limited role in neuroblastoma but rather acts through modulation of GSH levels.- Published
- 2019
- Full Text
- View/download PDF
31. Epigenetic enzymes influenced by oxidative stress and hypoxia mimetic in osteoblasts are differentially expressed in patients with osteoporosis and osteoarthritis.
- Author
-
Vrtačnik P, Zupan J, Mlakar V, Kranjc T, Marc J, Kern B, and Ostanek B
- Subjects
- Acetylation, Bone and Bones metabolism, Bone and Bones pathology, Cell Line, Chromatin genetics, Chromatin metabolism, Deferoxamine pharmacology, Epigenomics, Estradiol pharmacology, Female, Gene Expression Regulation, Histones metabolism, Humans, Hydrogen Peroxide metabolism, Hydrogen Peroxide pharmacology, Hypoxia enzymology, Male, Osteoarthritis enzymology, Osteoporosis enzymology, Oxidative Stress drug effects, Epigenesis, Genetic, Hypoxia genetics, Osteoarthritis genetics, Osteoarthritis metabolism, Osteoblasts metabolism, Osteoporosis genetics, Osteoporosis metabolism, Oxidative Stress genetics
- Abstract
Epigenetic mechanisms including posttranslational histone modifications and DNA methylation are emerging as important determinants of bone homeostasis. With our case-control study we aimed to identify which chromatin-modifying enzymes could be involved in the pathology of postmenopausal osteoporosis and osteoarthritis while co-regulated by estrogens, oxidative stress and hypoxia. Gene expression of HAT1, KAT5, HDAC6, MBD1 and DNMT3A affected by oxidative stress and hypoxia in an in vitro qPCR screening step performed on an osteoblast cell line was analysed in trabecular bone tissue samples from 96 patients. Their expression was significantly reduced in patients with postmenopausal osteoporosis and osteoarthritis as compared to autopsy controls and significantly correlated with bone mineral density and several bone histomorphometry-derived parameters of bone quality and quantity as well as indicators of oxidative stress, RANK/RANKL/OPG system and angiogenesis. Furthermore, oxidative stress increased DNA methylation levels at the RANKL and OPG promoters while decreasing histone acetylation levels at these two genes. Our study is the first to show that higher expression of HAT1, HDAC6 and MBD1 is associated with superior quantity as well as quality of the bone tissue having a more favourable trabecular structure.
- Published
- 2018
- Full Text
- View/download PDF
32. Creation of the Swiss group of Pharmacogenomics and personalised Therapy (SPT).
- Author
-
Amstutz U, Mlakar V, Curtis PH, Samer C, Baumann P, Bühlmann RP, Meier-Abt P, Meyer UA, van Schaik RHN, and Ansari M
- Subjects
- Humans, Switzerland, Pharmacogenetics organization & administration, Precision Medicine, Societies, Scientific organization & administration
- Published
- 2017
- Full Text
- View/download PDF
33. GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study.
- Author
-
Ansari M, Curtis PH, Uppugunduri CRS, Rezgui MA, Nava T, Mlakar V, Lesne L, Théoret Y, Chalandon Y, Dupuis LL, Schechter T, Bartelink IH, Boelens JJ, Bredius R, Dalle JH, Azarnoush S, Sedlacek P, Lewis V, Champagne M, Peters C, Bittencourt H, and Krajinovic M
- Abstract
Busulfan (BU) dose adjustment following therapeutic drug monitoring contributes to better outcome of hematopoietic stem cell transplantation (HSCT). Further improvement could be achieved through genotype-guided BU dose adjustments. To investigate this aspect, polymorphism within glutathione S transferase genes were assessed. Particularly, promoter haplotypes of the glutathione S transferase A1 ( GSTA1 ) were evaluated in vitro, with reporter gene assays and clinically, in a pediatric multi-center study (N =138) through association with BU pharmacokinetics (PK) and clinical outcomes. Promoter activity significantly differed between the GSTA1 haplotypes (p<0.001) supporting their importance in capturing PK variability. Four GSTA1 diplotype groups that significantly correlated with clearance (p=0.009) were distinguished. Diplotypes underlying fast and slow metabolizing capacity showed higher and lower BU clearance (ml/min/kg), respectively. GSTA1 diplotypes with slow metabolizing capacity were associated with higher incidence of sinusoidal obstruction syndrome, acute graft versus host disease and combined treatment-related toxicity (p<0.0005). Among other GST genes investigated, GSTP1 313GG correlated with acute graft versus host disease grade 1-4 (p=0.01) and GSTM1 non-null genotype was associated with hemorrhagic cystitis (p=0.003). This study further strengthens the hypothesis that GST diplotypes/genotypes could be incorporated into already existing population pharmacokinetic models for improving first BU dose prediction and HSCT outcomes. (N
o Clinicaltrials.gov identifier: NCT01257854. Registered 8 December 2010, retrospectively registered)., Competing Interests: CONFLICTS OF INTEREST H.B has acted as a consultant for Jazz Pharmaceuticals and obtained an education grant from them. H.B also acted as a consultant for Seattle Genetics. The authors declare that they have no other financial relationship(s) to disclose.- Published
- 2017
- Full Text
- View/download PDF
34. The Association of Combined GSTM1 and CYP2C9 Genotype Status with the Occurrence of Hemorrhagic Cystitis in Pediatric Patients Receiving Myeloablative Conditioning Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation.
- Author
-
Uppugunduri CRS, Storelli F, Mlakar V, Huezo-Diaz Curtis P, Rezgui A, Théorêt Y, Marino D, Doffey-Lazeyras F, Chalandon Y, Bader P, Daali Y, Bittencourt H, Krajinovic M, and Ansari M
- Abstract
Hemorrhagic cystitis (HC) is one of the complications of busulfan-cyclophosphamide (BU-CY) conditioning regimen during allogeneic hematopoietic stem cell transplantation (HSCT) in children. Identifying children at high risk of developing HC in a HSCT setting could facilitate the evaluation and implementation of effective prophylactic measures. In this retrospective analysis genotyping of selected candidate gene variants was performed in 72 children and plasma Sulfolane (Su, water soluble metabolite of BU) levels were measured in 39 children following treatment with BU-CY regimen. The cytotoxic effects of Su and acrolein (Ac, water soluble metabolite of CY) were tested on human urothelial cells (HUCs). The effect of Su was also tested on cytochrome P 450 (CYP) function in HepaRG hepatic cells. Cumulative incidences of HC before day 30 post HSCT were estimated using Kaplan-Meier curves and log-rank test was used to compare the difference between groups in a univariate analysis. Multivariate Cox regression was used to estimate hazard ratios with 95% confidence intervals (CIs). Multivariate analysis included co-variables that were significantly associated with HC in a univariate analysis. Cumulative incidence of HC was 15.3%. In the univariate analysis, HC incidence was significantly ( p < 0.05) higher in children older than 10 years (28.6 vs. 6.8%) or in children with higher Su levels (>40 vs. <11%) or in carriers of both functional GSTM1 and CYP2C9 (33.3 vs. 6.3%) compared to the other group. In a multivariate analysis, combined GSTM1 and CYP2C9 genotype status was associated with HC occurrence with a hazards ratio of 4.8 (95% CI: 1.3-18.4; p = 0.02). Ac was found to be toxic to HUC cells at lower concentrations (33 μM), Su was not toxic to HUC cells at concentrations below 1 mM and did not affect CYP function in HepaRG cells. Our observations suggest that pre-emptive genotyping of CYP2C9 and GSTM1 may aid in selection of more effective prophylaxis to reduce HC development in pediatric patients undergoing allogeneic HSCT. Article summary : (1) Children carrying functional alleles in GSTM1 and CYP2C9 are at high risk for developing hemorrhagic cystitis following treatment with busulfan and cyclophosphamide based conditioning regimen. (2) Identification of children at high risk for developing hemorrhagic cystitis in an allogeneic HSCT setting will enable us to evaluate and implement optimal strategies for its prevention. Trial registration : This study is a part of the trail "clinicaltrials.gov identifier: NCT01257854."
- Published
- 2017
- Full Text
- View/download PDF
35. 11q deletion in neuroblastoma: a review of biological and clinical implications.
- Author
-
Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, and Gumy-Pause F
- Subjects
- DNA Methylation genetics, Gene Regulatory Networks, Haploinsufficiency genetics, Humans, Chromosome Deletion, Chromosomes, Human, Pair 11 genetics, Neuroblastoma genetics
- Abstract
Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability. During the last 25 years, extensive efforts have been invested to identify the precise frequency of 11q aberrations in neuroblastoma, the recurrently involved genes, and to understand the molecular mechanisms of 11q deletion, but definitive answers are still unclear. In this review, it is our intent to compile and review the evidence acquired to date on 11q deletion in neuroblastoma.
- Published
- 2017
- Full Text
- View/download PDF
36. 8th Santorini Conference: Systems medicine and personalized health and therapy, Santorini, Greece, 3-5 October 2016.
- Author
-
Visvikis-Siest S, Aldasoro Arguinano AA, Stathopoulou M, Xie T, Petrelis A, Weryha G, Froguel P, Meier-Abt P, Meyer UA, Mlakar V, Ansari M, Papassotiropoulos A, Dedoussis G, Pan B, Bühlmann RP, Noyer-Weidner M, Dietrich PY, Van Schaik R, Innocenti F, März W, Bekris LM, and Deloukas P
- Subjects
- Greece, Humans, Precision Medicine, Systems Analysis
- Published
- 2017
- Full Text
- View/download PDF
37. Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use.
- Author
-
Mlakar V, Huezo-Diaz Curtis P, Satyanarayana Uppugunduri CR, Krajinovic M, and Ansari M
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Antineoplastic Agents pharmacokinetics, Child, Congresses as Topic, Enzyme Inhibitors administration & dosage, Enzyme Inhibitors adverse effects, Enzyme Inhibitors pharmacokinetics, Humans, Protein Binding, Antineoplastic Agents therapeutic use, Enzyme Inhibitors therapeutic use, Medical Oncology methods, Pediatrics methods, Pharmacogenetics methods
- Abstract
During the 3rd congress of the European Society of Pharmacogenomics and Personalised Therapy (ESPT) in Budapest in 2015, a preliminary meeting was held aimed at establishing a pediatric individualized treatment in oncology and hematology committees. The main purpose was to facilitate the transfer and harmonization of pharmacogenetic testing from research into clinics, to bring together basic and translational research and to educate health professionals throughout Europe. The objective of this review was to provide the attendees of the meeting as well as the larger scientific community an insight into the compiled evidence regarding current pharmacogenomics knowledge in pediatric oncology. This preliminary evaluation will help steer the committee's work and should give the reader an idea at which stage researchers and clinicians are, in terms of personalizing medicine for children with cancer. From the evidence presented here, future recommendations to achieve this goal will also be suggested., Competing Interests: The authors declare no conflict of interest.
- Published
- 2016
- Full Text
- View/download PDF
38. ADRA2A is involved in neuro-endocrine regulation of bone resorption.
- Author
-
Mlakar V, Jurkovic Mlakar S, Zupan J, Komadina R, Prezelj J, and Marc J
- Subjects
- Biomarkers metabolism, Bone Remodeling, Bone Resorption genetics, Bone Resorption physiopathology, Bone and Bones metabolism, Bone and Bones pathology, Cell Line, Tumor, Computational Biology, Enzyme Assays, Gene Expression Regulation, Genetic Association Studies, Genetic Predisposition to Disease, Humans, Immunohistochemistry, Luciferases metabolism, Neurosecretory Systems pathology, Osteoarthritis genetics, Osteoarthritis pathology, Osteoarthritis physiopathology, Osteoporosis genetics, Osteoporosis pathology, Osteoporosis physiopathology, Polymorphism, Single Nucleotide genetics, Receptors, Adrenergic, alpha-2 genetics, Bone Resorption pathology, Neurosecretory Systems metabolism, Receptors, Adrenergic, alpha-2 metabolism
- Abstract
Adrenergic stimulation is important for osteoclast differentiation and bone resorption. Previous research shows that this happens through β2-adrenergic receptor (AR), but there are conflicting evidence on presence and role of α2A-AR in bone. The aim of this study was to investigate the presence of α2A-AR and its involvement in neuro-endocrine signalling of bone remodelling in humans. Real-time polymerase chain reaction (PCR) and immunohistochemistry were used to investigate α2A-AR receptor presence and localization in bone cells. Functionality of rs553668 and rs1800544 single nucleotide polymorphism SNPs located in α2A-AR gene was analysed by qPCR expression on bone samples and luciferase reporter assay in human osteosarcoma HOS cells. Using real-time PCR, genetic association study between rs553668 A>G and rs1800544 C>G SNPs and major bone markers was performed on 661 Slovenian patients with osteoporosis. α2A-AR is expressed in osteoblasts and lining cells but not in osteocytes. SNP rs553668 has a significant influence on α2A-AR mRNA level in human bone samples through the stability of mRNA. α2A-AR gene locus associates with important bone remodelling markers (BMD, CTX, Cathepsin K and pOC). The results of this study are providing comprehensive new evidence that α2A-AR is involved in neuro-endocrine signalling of bone turnover and development of osteoporosis. As shown by our results the neurological signalling is mediated through osteoblasts and result in bone resorption. Genetic study showed association of SNPs in α2A-AR gene locus with bone remodelling markers, identifying the individuals with higher risk of development of osteoporosis., (© 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2015
- Full Text
- View/download PDF
39. Preparation of reference material for UGT1A1 (TA)n polymorphism genotyping.
- Author
-
Mlakar V, Mlakar SJ, Marc J, and Ostanek B
- Subjects
- Alleles, Chromatography, High Pressure Liquid, Gilbert Disease genetics, Humans, Reference Standards, Sequence Analysis, DNA, Genotyping Techniques standards, Glucuronosyltransferase genetics, Polymorphism, Genetic
- Abstract
Background: Gilbert's syndrome is one of the most common metabolic syndromes in the human population characterised by mild unconjugated hyperbilirubinemia resulting from reduced activity of the bilirubin conjugating enzyme UDP-glucuronosyltransferase (UGT1A1). Although Gilbert's syndrome is usually quite benign UGT1A1(TA)n genotyping is important in exclusion of more serious causes of hyperbilirubinemia and since it has significant implications for personalised medicine. The aim of our study was to develop plasmid based reference materials which could be used for UGT1A1(TA)n genotyping., Methods: Plasmids were generated using recombinant DNA technology and their number of repeats as well as the entire sequence verified by Sanger sequencing. Their suitability as reference materials was tested using sizing by capillary electrophoresis and denaturing high performance liquid chromatography., Results: Plasmids containing all four different alleles (TA)5, (TA)6, (TA)7 and (TA)8 that are present in the human population as well as a plasmid with (TA)4 repeats were successfully generated., Conclusions: Prepared plasmid reference materials allow the creation of all possible UGT1A1(TA)n polymorphism genotypes and can serve as an efficient substitute for the human genomic DNA reference material in routine genotyping and in the development of new genotyping tests., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
40. Highlights from the latest pharmacogenomic genome-wide association studies.
- Author
-
Mlakar V and Marc J
- Subjects
- Animals, Female, Humans, Male, Antimetabolites, Antineoplastic pharmacokinetics, Antineoplastic Agents, Hormonal therapeutic use, Biomedical Research, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Cell Cycle Proteins genetics, Chromosomes, Human, Pair 10, DNA-Binding Proteins genetics, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 genetics, Drug Industry, Exons, Genetic Loci, Genetic Variation, Genome-Wide Association Study, Metabolism genetics, Metformin pharmacology, Methotrexate pharmacokinetics, Neoplasm Proteins genetics, Organic Anion Transporters genetics, Polymorphism, Single Nucleotide, Protein Serine-Threonine Kinases genetics, Tamoxifen therapeutic use, Tumor Suppressor Proteins genetics
- Published
- 2013
- Full Text
- View/download PDF
41. Assessment of the tumourigenic and metastatic properties of SK-MEL28 melanoma cells surviving electrochemotherapy with bleomycin.
- Author
-
Todorovic V, Sersa G, Mlakar V, Glavac D, and Cemazar M
- Abstract
Background: Electrochemotherapy is a local treatment combining chemotherapy and electroporation and is highly effective treatment approach for subcutaneous tumours of various histologies. Contrary to surgery and radiation, the effect of electrochemotherapy on metastatic potential of tumour cells has not been extensively studied. The aim of the study was to evaluate the effect of electrochemotherapy with bleomycin on the metastatic potential of human melanoma cells in vitro., Materials and Methods: Viable cells 48 hours after electrochemotherapy were tested for their ability to migrate and invade through Matrigel coated porous membrane. In addition, microarray analysis and quantitative Real-Time PCR were used to detect changes in gene expression after electrochemotherapy., Results: Cell migration and invasion were not changed in melanoma cells surviving electrochemotherapy. Interestingly, only a low number of tumourigenesis related genes was differentially expressed after electrochemotherapy., Conclusions: Our data suggest that metastatic potential of human melanoma cells is not affected by electrochemotherapy with bleomycin, confirming safe role of electrochemotherapy in the clinics.
- Published
- 2012
- Full Text
- View/download PDF
42. Metastatic potential of melanoma cells is not affected by electrochemotherapy.
- Author
-
Todorovic V, Sersa G, Mlakar V, Glavac D, Flisar K, and Cemazar M
- Subjects
- Animals, Cell Line, Tumor, Cell Movement drug effects, Humans, Melanoma genetics, Mice, Middle Aged, Neoplasm Metastasis, Oligonucleotide Array Sequence Analysis, Skin Neoplasms genetics, Treatment Outcome, Antineoplastic Agents administration & dosage, Cisplatin administration & dosage, Electrochemotherapy methods, Melanoma drug therapy, Melanoma pathology, Skin Neoplasms drug therapy, Skin Neoplasms pathology
- Abstract
Electrochemotherapy is a local treatment combining chemotherapy and application of electric pulses to the tumour. Electrochemotherapy with bleomycin and cisplatin has shown its effectiveness in controlling local tumour growth in the treatment of malignant melanoma. However, the effect of electrochemotherapy on the metastatic potential of tumour cells is not known. Prevention of metastasis is an important aspect of successful treatment; however, it is known that metastasis can be induced by different treatment modalities. Therefore, the aim of this study was to evaluate the effect of electrochemotherapy with cisplatin on the metastatic potential of human malignant melanoma cells. Cells treated by electrochemotherapy with cisplatin were tested for their ability to migrate and invade through Matrigel-coated porous membrane. In addition, RNA was isolated from cells after treatment and differentially expressed genes were investigated by microarray analysis to evaluate the effect of electrochemotherapy with cisplatin on gene expression. There were no significant changes observed in cell migration and invasion of melanoma cells after electrochemotherapy. In addition, there were no changes observed in cell adhesion on Matrigel. Gene expression analysis showed that a very low number of genes were differentially expressed after electrochemotherapy with cisplatin. Two genes, LAMB3 and CD63 involved in cell migration, were both downregulated after electrochemotherapy with cisplatin and the expression of metastasis promoting genes was not increased after electrochemotherapy. Our data suggest that electrochemotherapy does not increase the metastatic behaviour of human melanoma cells.
- Published
- 2011
- Full Text
- View/download PDF
43. Oligonucleotide DNA microarray profiling of lung adenocarcinoma revealed significant downregulation and deletions of vasoactive intestinal peptide receptor 1.
- Author
-
Mlakar V, Strazisar M, Sok M, and Glavac D
- Subjects
- Aged, Down-Regulation, Female, Gene Deletion, Gene Expression Profiling, Humans, Male, Middle Aged, Oligonucleotide Array Sequence Analysis, Osteopontin genetics, Polymerase Chain Reaction, Adenocarcinoma genetics, Lung Neoplasms genetics, Receptors, Vasoactive Intestinal Polypeptide, Type I genetics
- Abstract
The purpose of this study was to find novel gene(s) involved in the development of lung adenocarcinoma (AD). Using DNA microarrays, we identified 31 up-regulated and 8 downregulated genes in 12 AD. Real time PCR was used to measure expression of VIPR1 and SPP1 mRNA and possible losses or gains of genes in 32 AD. We describe significant upregulation of the SPP1 gene, downregulation of VIPR1, and losses of the VIPR1 gene. Our findings complement a proposed VIPR1 tumor suppressor role, in which deletions in the 3p22 chromosome region are an important mechanism leading to loss of the VIPR1 gene.
- Published
- 2010
- Full Text
- View/download PDF
44. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma.
- Author
-
Strazisar M, Mlakar V, and Glavac D
- Subjects
- Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung physiopathology, Cell Line, Tumor, Cell Transformation, Neoplastic, DNA Mutational Analysis, Female, Genes, p53 genetics, Genes, ras genetics, Humans, Loss of Heterozygosity, Lung pathology, Lung Neoplasms pathology, Lung Neoplasms physiopathology, Male, Neoplasm Staging, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins c-mdm2 genetics, Proto-Oncogene Proteins c-mdm2 metabolism, Tumor Suppressor Proteins metabolism, Carcinoma, Non-Small-Cell Lung genetics, Down-Regulation, Lung metabolism, Lung Neoplasms genetics, Mutation, Protein Serine-Threonine Kinases genetics, Tumor Suppressor Proteins genetics
- Abstract
LATS2 is a new member of the LATS tumour suppressor family. The human LATS2 gene is located at chromosome 13q11-12, a hot spot (67%) for loss of heterozygosity (LOH) in non-small cell lung cancer (NSCLC). We screened 129 non-small cell lung cancer samples and 13 lung cancer cell lines, initially for mutations in the LATS2 gene and subsequently for mutations in P53 and K-RAS genes. Either polymorphisms or mutations were identified in over 50 percent of analysed tumours. A novel missense mutation, S1073R, and a large deletion of 8 amino acids in the PAPA-repeat region were detected in 9 and 2 NSCLC tumours, respectively. Those mutations were not identified in the 13 lung cancer cell lines. Mutations were tumour specific and were absent from adjacent normal tissue and healthy controls. Down-regulation of the LATS2 gene was observed in most NSCLC tumours but was not related to any mutation or polymorphism. Tumours with a LATS2 mutation often also harbour a P53 but not K-RAS gene mutation and were mostly in an advanced stage of development, with regional lymph node involvement.
- Published
- 2009
- Full Text
- View/download PDF
45. Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma.
- Author
-
Strazisar M, Mlakar V, Rott T, and Glavac D
- Subjects
- AMP-Activated Protein Kinase Kinases, Adenocarcinoma enzymology, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Carcinoma, Large Cell enzymology, Carcinoma, Large Cell pathology, Carcinoma, Squamous Cell enzymology, Carcinoma, Squamous Cell pathology, Case-Control Studies, Chromatography, High Pressure Liquid, Cyclooxygenase 2 genetics, DNA Mutational Analysis methods, Exons, Female, Gene Silencing, Genes, ras, Humans, Introns, Lung Neoplasms enzymology, Lung Neoplasms pathology, Male, Middle Aged, Adenocarcinoma genetics, Carcinoma, Large Cell genetics, Carcinoma, Squamous Cell genetics, Gene Expression Regulation, Enzymologic, Gene Expression Regulation, Neoplastic, Lung Neoplasms genetics, Mutation, Protein Serine-Threonine Kinases genetics
- Abstract
Somatic LKB1 serine/threonine kinase alterations are rare in sporadic cancers, with the exception lung adenocarcinoma, but no mutations in squamous cell or large cell primary carcinoma were discovered. We screened the LKB1 gene in 129 primary nonsmall cell lung carcinomas, adjacent healthy lung tissue, and control blood samples. Forty-five percent of nonsmall cell lung tumors harbored either intron or exon alterations. We identified R86G, F354L, Y272Y and three polymorphisms: 290+36G/T, 386+156G/T, and 862+145C/T (novel). R86G (novel) and F354L mutations were found in six squamous cell carcinomas and three large cell cancer carcinomas, but not in the adjacent healthy tissue or controls samples. The F354L mutation was found in advanced squamous cell carcinomas with elevated COX-2 expression, rare P53, and no K-RAS mutation. Results indicate that the LKB1 gene is changed in a certain proportion of nonsmall cell lung tumors, predominately in advanced squamous lung carcinoma. Inactivation of the gene takes place via the C-terminal domain and could be related to mechanisms influencing tumor initiation, differentiation, and metastasis.
- Published
- 2009
- Full Text
- View/download PDF
46. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC).
- Author
-
Strazisar M, Mlakar V, and Glavac D
- Subjects
- Adenocarcinoma enzymology, Adenocarcinoma genetics, Adenocarcinoma metabolism, Aged, Carcinoma, Large Cell enzymology, Carcinoma, Large Cell genetics, Carcinoma, Large Cell metabolism, Carcinoma, Non-Small-Cell Lung enzymology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Squamous Cell enzymology, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell metabolism, Chemotactic Factors genetics, Cyclooxygenase 2 genetics, Female, Humans, Lung Neoplasms enzymology, Lung Neoplasms genetics, Male, Middle Aged, Neoplasm Staging, Protein Serine-Threonine Kinases genetics, Proto-Oncogene Proteins c-mdm2 genetics, S100 Proteins genetics, Telomerase genetics, Tumor Suppressor Proteins genetics, Carcinoma, Non-Small-Cell Lung metabolism, Chemotactic Factors metabolism, Cyclooxygenase 2 metabolism, Lung Neoplasms metabolism, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins c-mdm2 metabolism, S100 Proteins metabolism, Telomerase metabolism, Tumor Suppressor Proteins metabolism
- Abstract
Several studies have reported different expression levels of certain genes in NSCLC, mostly related to the stage and advancement of the tumours. We investigated 65 stage I-III NSCLC tumours: 32 adenocarcinomas (ADC), 26 squamous cell carcinomas (SCC) and 7 large cell carcinomas (LCC). Using the real-time reverse transcription polymerase chain reaction (RT-PCR), we analysed the expression of the COX-2, hTERT, MDM2, LATS2 and S100A2 genes and researched the relationships between the NSCLC types and the differences in expression levels. The differences in the expression levels of the LATS2, S100A2 and hTERT genes in different types of NSCLC are significant. hTERT and COX-2 were over-expressed and LATS2 under-expressed in all NSCLC. We also detected significant relative differences in the expression of LATS2 and MDM2, hTERT and MDM2 in different types of NSCLC. There was a significant difference in the average expression levels in S100A2 for ADC and SCC. Our study shows differences in the expression patterns within the NSCLC group, which may mimic the expression of the individual NSCLC type, and also new relationships in the expression levels for different NSCLC types.
- Published
- 2009
- Full Text
- View/download PDF
47. DNA microarrays and their use in dermatology.
- Author
-
Mlakar V and Glavac D
- Subjects
- Gene Expression, Humans, Keratinocytes metabolism, Melanocytes metabolism, Ultraviolet Rays, Gene Expression Profiling methods, Keratinocytes radiation effects, Melanocytes radiation effects, Melanoma genetics, Oligonucleotide Array Sequence Analysis methods, Psoriasis genetics
- Abstract
Multiple different DNA microarray technologies are available on the market today. They can be used for studying either DNA or RNA with the purpose of identifying and explaining the role of genes involved in different processes. This paper reviews different DNA microarray platforms available for such studies and their usage in cases of malignant melanomas, psoriasis, and exposure of keratinocytes and melanocytes to UV illumination.
- Published
- 2007
48. Cation-induced transcriptional regulation of the dlt operon of Staphylococcus aureus.
- Author
-
Koprivnjak T, Mlakar V, Swanson L, Fournier B, Peschel A, and Weiss JP
- Subjects
- Bacterial Proteins genetics, Bacterial Proteins metabolism, Base Sequence, Chloramphenicol O-Acetyltransferase genetics, Chloramphenicol O-Acetyltransferase metabolism, DNA Primers, RNA, Bacterial genetics, RNA, Messenger genetics, Restriction Mapping, Staphylococcus aureus drug effects, Staphylococcus aureus growth & development, Gene Expression Regulation, Bacterial drug effects, Lipopolysaccharides pharmacology, Operon, Staphylococcus aureus genetics, Teichoic Acids pharmacology, Transcription, Genetic drug effects
- Abstract
Lipoteichoic and wall teichoic acids (TA) are highly anionic cell envelope-associated polymers containing repeating polyglycerol/ribitol phosphate moieties. Substitution of TA with D-alanine is important for modulation of many cell envelope-dependent processes, such as activity of autolytic enzymes, binding of divalent cations, and susceptibility to innate host defenses. D-Alanylation of TA is diminished when bacteria are grown in medium containing increased NaCl concentrations, but the effects of increased salt concentration on expression of the dlt operon encoding proteins mediating D-alanylation of TA are unknown. We demonstrate that Staphylococcus aureus transcriptionally represses dlt expression in response to high concentrations of Na(+) and moderate concentrations of Mg(2+) and Ca(2+) but not sucrose. Changes in dlt mRNA are induced within 15 min and sustained for several generations of growth. Mg(2+)-induced dlt repression depends on the ArlSR two-component system. Northern blotting, reverse transcription-PCR, and SMART-RACE analyses suggest that the dlt transcript begins 250 bp upstream of the dltA start codon and includes an open reading frame immediately upstream of dltA. Chloramphenicol transacetylase transcriptional fusions indicate that a region encompassing the 171 to 325 bp upstream of dltA is required for expression and Mg(2+)-induced repression of the dlt operon in S. aureus.
- Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.